T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

EXPERTS have warned over hundreds rushed to hospital after using weight loss jabs – as half a million Brits now use the ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Wegovy's success, coupled with the ... as Wegovy’s primary competitor. Tirzepatide’s dual agonism mechanism allows for 20% average body weight loss in patients. Recent head-to-head trial ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Weight loss drugs like Ozempic ... market this year after their global success. In 2023, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...